AMB-05X

Phase 2Biologic

AAmMax Bio, Inc.

AMB-05X is one of 86 biologic programs targeting Giant Cell Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell TumorActive, not recruiting

Colorectal CancerActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Giant Cell TumorPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Eylea

Regeneron

Preclinical

5 2

AMB-05X

AAmMax Bio, Inc.

Phase 2

1 3

Emend IV

PORTRAZZA

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Andriol

AAuxilium

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Vascepa

AAmarin Pharma Inc.

Preclinical

1 10

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Colorectal Cancer

NCT06617858

Clinical

Trials by Indication[1]

Giant Cell Tumor2 trials

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

Completed·AAmMax Bio, Inc.·Phase 2·NCT04731675·11 enrolled

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

Terminated·AAmMax Bio, Inc.·Phase 2·NCT04938180·4 enrolled

Safety and Efficacy1 trial

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Completed·AAmMax Bio, Inc.·Phase 2·NCT05349643·20 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

Withdrawn·AAmMax Bio, Inc.·Phase 2·NCT05349760

Colorectal Cancer1 trial

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06617858·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AMB-05X. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMB-05X compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMB-05X. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AmMax Bio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAmMax Bio, Inc.

AMB-05X

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Giant Cell Tumor2 trials

Safety and Efficacy1 trial

Idiopathic Pulmonary Fibrosis1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News